Brickell Biotech Inc. [NASDAQ: BBI] gained 4.39% on the last trading session, reaching $1.19 price per share at the time. The company report on January 19, 2021 that Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology.
Commercial launch of ECCLOCK® in Japan currently underway by Development Partner, Kaken Pharmaceutical.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced that the efficacy and safety results from the pivotal Phase 3 study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology1.
Brickell Biotech Inc. represents 53.52 million in outstanding shares, while the company has a total market value of $63.14 million with the latest information. BBI stock price has been found in the range of $1.17 to $1.2799.
If compared to the average trading volume of 3.29M shares, BBI reached a trading volume of 4857007 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Brickell Biotech Inc. [BBI]:
Lake Street have made an estimate for Brickell Biotech Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 28, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on August 25, 2020, representing the official price target for Brickell Biotech Inc. stock.
The Average True Range (ATR) for Brickell Biotech Inc. is set at 0.13, with the Price to Sales ratio for BBI stock in the period of the last 12 months amounting to 25.26. The Price to Book ratio for the last quarter was 1.78, with the Price to Cash per share for the same quarter was set at 0.38.
Trading performance analysis for BBI stock
Brickell Biotech Inc. [BBI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.21. With this latest performance, BBI shares dropped by -2.46% in over the last four-week period, additionally plugging by 29.77% over the last 6 months – not to mention a drop of -25.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBI stock in for the last two-week period is set at 60.90, with the RSI for the last a single of trading hit 60.55, and the three-weeks RSI is set at 61.15 for Brickell Biotech Inc. [BBI]. The present Moving Average for the last 50 days of trading for this stock 0.9005, while it was recorded at 1.1160 for the last single week of trading, and 0.9260 for the last 200 days.
Brickell Biotech Inc. [BBI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Brickell Biotech Inc. [BBI] shares currently have an operating margin of -309.06. Brickell Biotech Inc.’s Net Margin is presently recorded at -301.59.
Return on Total Capital for BBI is now -86.63, given the latest momentum, and Return on Invested Capital for the company is -84.66. Return on Equity for this stock declined to -84.76, with Return on Assets sitting at -67.75. When it comes to the capital structure of this company, Brickell Biotech Inc. [BBI] has a Total Debt to Total Equity ratio set at 1.99. Additionally, BBI Total Debt to Total Capital is recorded at 1.95, with Total Debt to Total Assets ending up at 0.83. Long-Term Debt to Equity for the company is recorded at 0.96, with the Long-Term Debt to Total Capital now at 0.94.
Reflecting on the efficiency of the workforce at the company, Brickell Biotech Inc. [BBI] managed to generate an average of -$1,591,800 per employee.Brickell Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.50.
Brickell Biotech Inc. [BBI]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Brickell Biotech Inc. posted -1.19/share EPS, while the average EPS was predicted by analysts to be reported at -1.19/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBI.
An analysis of insider ownership at Brickell Biotech Inc. [BBI]
There are presently around $4 million, or 10.70% of BBI stock, in the hands of institutional investors. The top three institutional holders of BBI stocks are: PALISADE CAPITAL MANAGEMENT LLC/NJ with ownership of 950,905, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; SABBY MANAGEMENT, LLC, holding 721,887 shares of the stock with an approximate value of $0.86 million in BBI stocks shares; and VANGUARD GROUP INC, currently with $0.76 million in BBI stock with ownership of nearly 79.688% of the company’s market capitalization.
Positions in Brickell Biotech Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 9 institutional holders increased their position in Brickell Biotech Inc. [NASDAQ:BBI] by around 1,193,957 shares. Additionally, 9 investors decreased positions by around 1,690,903 shares, while 11 investors held positions by with 287,948 shares. The mentioned changes placed institutional holdings at 3,172,808 shares, according to the latest SEC report filing. BBI stock had 6 new institutional investments in for a total of 779,599 shares, while 7 institutional investors sold positions of 1,689,529 shares during the same period.